CCM Duopharma aims to boost biosimilars’ contribution to revenue

SHAH ALAM: Pharmaceutical company CCM Duopharma Biotech Bhd (CCMD) is targeting to raise revenue contribution from its biosimilar products to beyond 25% from 22% currently, after identifying the segment as one of the group’s key growth areas in the near term following the government’s higher allocation for health services under Budget 2019.

Under the budget, the government has raised the sum set aside for health services by 7.8% or RM2 billion to RM29 billion, compared with 2018’s allocation.


Warning: A non-numeric value encountered in /home/customer/www/bionews.bioeconomycorporation.my/public_html/wp-content/themes/Newspaper/includes/wp_booster/td_block.php on line 352